Abeona Therapeutics Inc. (0H7R.L)
USD 4.91
(1.42%)
USD 4.91
(1.42%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 48.5 Million USD | -36.59% |
| 2022 | 42.09 Million USD | -24.71% |
| 2021 | 55.9 Million USD | 5.68% |
| 2020 | 52.9 Million USD | -22.67% |
| 2019 | 68.41 Million USD | 16.34% |
| 2018 | 58.8 Million USD | 110.53% |
| 2017 | 27.93 Million USD | 16.65% |
| 2016 | 23.94 Million USD | 28.32% |
| 2015 | 18.66 Million USD | -31.31% |
| 2014 | 27.16 Million USD | 866.42% |
| 2013 | 2.81 Million USD | -80.01% |
| 2012 | 14.06 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 16.19 Million USD | 19.04% |
| 2024 Q1 | 13.6 Million USD | 8.95% |
| 2023 Q3 | 10.58 Million USD | -25.89% |
| 2023 FY | 48.5 Million USD | 15.22% |
| 2023 Q2 | 14.28 Million USD | 28.08% |
| 2023 Q4 | 12.48 Million USD | 18.0% |
| 2023 Q1 | 11.15 Million USD | 0.95% |
| 2022 FY | 42.09 Million USD | -24.71% |
| 2022 Q3 | 8.29 Million USD | -8.83% |
| 2022 Q2 | 9.09 Million USD | -33.38% |
| 2022 Q1 | 13.65 Million USD | -14.6% |
| 2022 Q4 | 11.04 Million USD | 33.15% |
| 2021 Q2 | 12.61 Million USD | -6.63% |
| 2021 Q4 | 15.99 Million USD | 15.97% |
| 2021 Q3 | 13.78 Million USD | 9.29% |
| 2021 Q1 | 13.51 Million USD | 64.04% |
| 2021 FY | 55.9 Million USD | 5.68% |
| 2020 Q3 | 5.27 Million USD | -17.15% |
| 2020 Q2 | 6.37 Million USD | -84.61% |
| 2020 FY | 52.9 Million USD | -22.67% |
| 2020 Q1 | 41.39 Million USD | 508.18% |
| 2020 Q4 | 8.23 Million USD | 56.03% |
| 2019 Q2 | 7.66 Million USD | 4.81% |
| 2019 Q4 | 6.8 Million USD | 1.1% |
| 2019 Q3 | 6.73 Million USD | -12.22% |
| 2019 FY | 68.41 Million USD | 16.34% |
| 2019 Q1 | 7.31 Million USD | -18.9% |
| 2018 Q1 | 3.05 Million USD | -6.35% |
| 2018 Q3 | 5.47 Million USD | 11.35% |
| 2018 Q4 | 9.02 Million USD | 64.79% |
| 2018 FY | 58.8 Million USD | 110.53% |
| 2018 Q2 | 4.91 Million USD | 61.11% |
| 2017 Q3 | 2.3 Million USD | -19.13% |
| 2017 Q2 | 2.84 Million USD | -12.93% |
| 2017 Q1 | 3.27 Million USD | -55.34% |
| 2017 FY | 27.93 Million USD | 16.65% |
| 2017 Q4 | 3.25 Million USD | 41.45% |
| 2016 Q3 | 2.81 Million USD | -59.42% |
| 2016 FY | 23.94 Million USD | 28.32% |
| 2016 Q4 | 7.32 Million USD | 160.56% |
| 2016 Q2 | 6.92 Million USD | 19.38% |
| 2016 Q1 | 5.8 Million USD | 125.84% |
| 2015 Q4 | 2.57 Million USD | -60.15% |
| 2015 Q2 | 4.4 Million USD | 95.09% |
| 2015 Q1 | 2.26 Million USD | -81.17% |
| 2015 FY | 18.66 Million USD | -31.31% |
| 2015 Q3 | 6.44 Million USD | 46.27% |
| 2014 FY | 27.16 Million USD | 866.42% |
| 2014 Q4 | 12 Million USD | 664.88% |
| 2014 Q2 | 12.64 Million USD | 1226.65% |
| 2014 Q3 | 1.56 Million USD | -87.59% |
| 2014 Q1 | 953 Thousand USD | 3.03% |
| 2013 FY | 2.81 Million USD | -80.01% |
| 2013 Q1 | 2.87 Million USD | -84.87% |
| 2013 Q2 | 1.15 Million USD | -59.8% |
| 2013 Q3 | 289 Thousand USD | -74.96% |
| 2013 Q4 | 924.99 Thousand USD | 220.07% |
| 2012 FY | 14.06 Million USD | 0.0% |
| 2012 Q4 | 18.97 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| uniQure N.V. | 285.08 Million USD | 82.987% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -299.489% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 97.707% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 88.136% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 97.306% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 88.659% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 13.01% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 82.407% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 89.818% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 97.223% |
| bluebird bio, Inc. | 240.23 Million USD | 79.81% |
| Blueprint Medicines Corporation | 722.86 Million USD | 93.29% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 65.955% |
| Imunon, Inc. | 21.03 Million USD | -130.628% |
| Adicet Bio, Inc. | 152.03 Million USD | 68.099% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 86.842% |
| Dynavax Technologies Corporation | 219.14 Million USD | 77.868% |
| Editas Medicine, Inc. | 247.3 Million USD | 80.388% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 95.354% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 82.162% |
| Exelixis, Inc. | 1.58 Billion USD | 96.943% |
| FibroGen, Inc. | 398.11 Million USD | 87.817% |
| Geron Corporation | 70.44 Million USD | 31.145% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 83.796% |
| Heron Therapeutics, Inc. | 120.65 Million USD | 59.802% |
| Illumina, Inc. | 3.81 Billion USD | 98.728% |
| Incyte Corporation | 1.19 Billion USD | 95.926% |
| Insmed Incorporated | 949.26 Million USD | 94.891% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 91.206% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 93.779% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 89.246% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 97.638% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -23.878% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 95.548% |
| Evolus, Inc. | 189.75 Million USD | 74.44% |
| Myriad Genetics, Inc. | 600.1 Million USD | 91.918% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 96.962% |
| OPKO Health, Inc. | 574.68 Million USD | 91.56% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 96.436% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 90.832% |
| Verastem, Inc. | 92.08 Million USD | 47.329% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.881% |
| Waters Corporation | 943.51 Million USD | 94.859% |
| Zoetis Inc. | 2.76 Billion USD | 98.246% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 98.984% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 99.527% |
| Biogen Inc. | 5.2 Billion USD | 99.068% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 78.79% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 98.277% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -248.693% |
| Homology Medicines, Inc. | 9.87 Million USD | -391.159% |
| Nektar Therapeutics | 190.9 Million USD | 74.593% |
| TG Therapeutics, Inc. | 198.47 Million USD | 75.563% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 51.896% |
| Perrigo Company plc | 1.52 Billion USD | 96.827% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -8.586% |